JAMA Current Issue

Risankizumab for Ulcerative Colitis—Reply

In Reply We appreciate the comments by Dr Li about our recent phase 3 risankizumab ulcerative colitis induction (INSPIRE) and maintenance (COMMAND) studies.

Feb 18, 2025 - 17:51
 0
In Reply We appreciate the comments by Dr Li about our recent phase 3 risankizumab ulcerative colitis induction (INSPIRE) and maintenance (COMMAND) studies.
Read More

Tags:

Previous Article

Evidence Lacking for Many AI Tools Used in Primary Care

Next Article

Expanding Palliative Care Access—Bridging Gaps in Diverse Clinical Settings

Related Posts

Flavored E-Cigarette Bans Might Increase Young Adults’ ...

Feb 25, 2025  0

Using AI to Help Respond to Patient Messages

Feb 25, 2025  0

Combination Drug Therapy May Better Alleviate PTSD Symp...

Feb 18, 2025  0